Search Videos and More
News
Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma
Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions.Dana-Farber Research Publication, 8.1.2021
News
Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs Launch Precision Genomics Initiative for Pediatric Cancer
In a pioneering collaboration aimed at transforming pediatric cancer diagnostics and research, Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs have announced the formation of BrightSeq — Boston Research in Innovative Genomics for Hematologic and Tumor Sequencing — collaborative clinical research and testing initiative.
News
When Science Moves Mountains
How Dana-Farber Research Delivered New Medicines and Long-Range Hope for a Patient With Metastatic Breast Cancer
News
Dana-Farber Research News 08.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.
News
Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
Results from this study show that already approved precision medicines have the potential benefit for children with FGFR-altered gliomas.
News
U.S. News & World Report Names Dana-Farber Brigham Cancer Center Among Nation’s Best for 2025-2026
Recognition marks a quarter of a century of excellence
News
Study Paves Path to Improved Diagnosis, Treatment of NUT Carcinoma
Dana-Farber research uncovered the potential for underdiagnosis of this aggressive cancer and identified additional tests required for an accurate diagnosis.
News
Global Rise in Many Early-Onset GI Cancers Detailed in Two Dana-Farber Reviews, With Colorectal Cancer Leading the Trend
Early-onset gastrointestinal (GI) cancers are rising at alarming rates worldwide and, in the U.S., are increasing faster than any other type of early-onset cancer, including breast cancer, according to two recent literature reviews from Dana-Farber Cancer Institute.
News
Dana-Farber Research News 07.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 16 through June 30.
News
TILs: What Are They and How Are They Used in Cancer Treatment?
Tumor-infiltrating lymphocyte, or TIL, therapy uses a patient’s own immune system T cells to fight cancer.
News
Modified Personalized Cancer Vaccine Generates Powerful Immune Response
Dana-Farber researchers designed a novel formulation and delivery approach for the NeoVax personalized cancer vaccine and observed strong vaccine-specific immune responses in patients with melanoma.